- Duración
- 24/11/2020 - 30/5/2022
- Coordinador
- Drugs for Neglected Diseases initiative (DNDi)
- Financiadores
- German Federal Ministry of Education and Research (BMBF) through a credit for reconstruction (KfW) and the global health agency Unitaid, as part of ACT-A
- Página web
- https://anticov.org/news/
The aim of the ANTICOV clinical trial is to respond to the urgent need to identify treatments that can be used in the early treatment of mild to moderate cases of COVID-19 to prevent hospitalisation surges that could overwhelm fragile and overburdened health systems in Africa.
The clinical trial will be carried out at 19 sites in 13 African countries by the ANTICOV consortium, which includes 26 African organisations and well-known international research and development institutions, including ISGlobal. The project is being coordinated by the Drugs for Neglected Diseases initiative.
ANTICOV will assess the safety and efficacy of different treatments in 2000 to 3000 patients with mild to moderate disease who have not been hospitalised. Trials will take place in Burkina Faso, Cameroon, Côte d’Ivoire, Ethiopia, Ghana, Guinea, Equatorial Guinea, Kenya, Mali, Mozambique, the Democratic Republic of Congo (DRC), Sudan and Uganda. The aim is to ascertain whether early treatment can prevent progression of COVID-19 to severe disease and potentially limit transmission.
ISGlobal’s role in the ANTICOV project is twofold. First, the Institute will work together with two of the hospitals where clinical trials are being carried out, both located in Mozambique: the Manhiça Health Research Centre (CISM) and the Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC), which forms part of the country’s National Institute of Health.
In addition, ISGlobal is co-leader, together with the Institute of Tropical Medicine (ITM) in Antwerp (Belgium), of one of the project’s two ancillary studies. This is an immunology study that will be carried out in 7 countries to analyse whether the treatments tested in the clinical trial in patients with mild to moderate COVID-19 alter the strength or duration of immune responses to SARS-CoV-2. The researchers will study antibodies and T-lymphocytes and compare the immune responses of symptomatic and asymptomatic patients
Nuestro equipo
PI
-
DENISE NANICHE Directora científica
Co-PI and Technical coordinator
-
Elisa López Varela Associated Researcher
Scientific Leader of the IMMUNO study and Co-PI of the IMMUNO Study
-
Gemma Moncunill Assistant Research Professor
Team
-
Sheila Fernández-Luis
-
Daniel Iñiguez Monitor de ensayos clínicos
-
Quique Bassat Director general
-
Laura De La Fuente Investigadora posdoctoral
-
Carole Amroune Project Manager
-
Elisabeth Salvo Project manager
Otros proyectos
Ver proyectos pasadosINTE-AFRICA
Integrating and decentralizing diabetes and hypertension services in Africa
COMBACTE
Combatiendo la Resistencia Bacteriana en Europa
GAMA
Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting
Evaluación de estrategias para la erradicación de la enfermedad del Pian
Erradicación del Pian
Novel Marine Biomolecules against Biofilm (NoMorFilm)
Application to medical devices
COMBACTE-CARE
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
MAMAH
Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women
ICARIA
Improving Care through Azithromycin Research for Infants in Africa
PreFIT
Predicting the Future: Incipient Tuberculosis
Predicting the Future: Incipient Tuberculosis
Encuesta serológica Cendea de Cizur
Cendea de Cizur
Projecte de Recerca en Resposta Immunitària i Epidemiologia de Malalties Infeccioses
Conèixer la propagació. Entendre la protecció
Stool4TB
Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV
TB-RECONNECT
Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status
SToolNIH
Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring
ALIA - Las ciudades y la salud
Planificación urbana, medio ambiente y salud | Clima y salud | Resistencias Antimicrobianas
END-VOC
ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)
TwinAir
Digital Twins Enabled Indoor Air Quality Management for Healthy Living
Estudio de la propagación de bacterias y genes de resistencia a los antibióticos en el ciclo integral del agua, en el área metropolitana de Barcelona
Propagación de la resistencia en aguas
Nuevos complejos de oro (III) frente a bacterias multirresistentes
Project Code: DTS21/00004
Desarrollo de dos nuevas estrategias terapéuticas (inhibidores de bombas de expulsion y ARN antisentido) activos frente a bacterias mutliresistentes
Más allá de la supresión vírica del VIH: un cuarto noventa para mejorar la salud de personas viviendo con el VIH en España
Project Code: PI20/01654
ENDÈMIC
Community knowledge generation through scientific culture, urban ecology and art
EpiGen
Building Scalable Pathogen Genomic Epidemiology in Ethiopia
Hepatitis C Free Baleares
Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.
FLAVOBAC
Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias